Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage


Phase N/A Results

Trial Description

To test the hypothesis that the modification of platelet behavior might reduce the incidence of ischemic deficits following surgery for subarachnoid hemorrhage.


  • Dipyridamole (Persantine┬«)Drug
    Intervention Desc: Platelet aggregation inhibitor

Trial Design

Single-blind, controlled trial of 677 patients.

Patient Involvement

Patients were randomized immediately upon admission to receive either placebo or dipyridamole 100 mg/day orally or 10 mg/day intravenously. Patients who underwent surgery continued the treatment for 3 months postoperatively.


Type Measure Time Frame Safety Issue
Primary Glasgow Outcome Scale and specific neurological deficits at 3 months postoperatively.